These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 31134762)

  • 1. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
    Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
    Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients.
    Zmrzljak UP; Košir R; Krivokapić Z; Radojković D; Nikolić A
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33669856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer.
    Huang F; Yang Y; Chen X; Jiang H; Wang H; Shen M; Yu Y; Liu T; Pan B; Wang B; Guo W
    Clin Biochem; 2021 Jun; 92():46-53. PubMed ID: 33737000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
    Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
    J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of
    Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
    World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
    Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
    Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
    Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
    Xie W; Xie L; Song X
    Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
    Möhrmann L; Huang HJ; Hong DS; Tsimberidou AM; Fu S; Piha-Paul SA; Subbiah V; Karp DD; Naing A; Krug A; Enderle D; Priewasser T; Noerholm M; Eitan E; Coticchia C; Stoll G; Jordan LM; Eng C; Kopetz ES; Skog J; Meric-Bernstam F; Janku F
    Clin Cancer Res; 2018 Jan; 24(1):181-188. PubMed ID: 29051321
    [No Abstract]   [Full Text] [Related]  

  • 13. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
    Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
    Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.
    Vivancos A; Aranda E; Benavides M; Élez E; Gómez-España MA; Toledano M; Alvarez M; Parrado MRC; García-Barberán V; Diaz-Rubio E
    Sci Rep; 2019 Jun; 9(1):8976. PubMed ID: 31222012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients.
    Damin F; Galbiati S; Soriani N; Burgio V; Ronzoni M; Ferrari M; Chiari M
    PLoS One; 2018; 13(12):e0207876. PubMed ID: 30562355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of KRAS mutation in colorectal cancer patients' cfDNA with droplet digital PCR].
    Luo Y; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):407-420. PubMed ID: 29577691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
    Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
    Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
    Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
    Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients.
    Crisafulli G; Mussolin B; Cassingena A; Montone M; Bartolini A; Barault L; Martinetti A; Morano F; Pietrantonio F; Sartore-Bianchi A; Siena S; Di Nicolantonio F; Marsoni S; Bardelli A; Siravegna G
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32149725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.